Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia

  • S. Daenen
  • Z. Erjavec
  • D. R. A. Uges
  • H. G. De Vries-Hospers
  • P. De Jonge
  • M. R. Halie
Article

Abstract

Twelve febrile patients with severe neutropenia, who had undergone aggressive chemotherapy for acute myeloid leukemia, were treated empirically with a continuous infusion of ceftazidime 100 mg/kg/day after a 500 mg loading dose, in order to study the pharmacokinetics of ceftazidime after continuous infusion and to examine the clinical applicability of continuous infusion in this patient population. Three patients had a slight decrease in renal function. All patients attained a steady-state ceftazidime serum level of >20 µg/ml within 180 to 240 min, which was considered effective against most pathogens in neutropenic patients. The median volume of distribution for the patient group was 29.1 I, the elimination half-life was 2.5 h and the clearance of ceftazidime was 7.7 l/h. A subnormal kidney function influenced half-lives and clearance (but not volume of distribution), as expected. When precautions were taken to avoid known interactions between ceftazidime and other compounds to be infused simultaneously, continuous infusion of ceftazidime was applicable for treatment of neutropenic patients without major side effects.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Eagle H, Fleischman R, Levy M: “Continuous” vs “discontinuous” therapy with penicillin. The effect of the interval between injections on therapeutic efficacy. New England Journal of Medicine 1953, 248: 481–488.PubMedGoogle Scholar
  2. 2.
    Van Etta LL, Kravitz GR, Russ TE, Fasching CE, Gerding DN, Peterson LR: Effect of method of administration on extravascular penetration of four antibiotics. Antimicrobial Agents and Chemotherapy 1982, 21: 873–880.PubMedGoogle Scholar
  3. 3.
    Thauvin C, Eliopoulos GM, Willey S, Wennersten C, Moellering RC.: Continuous infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrobial Agents and Chemotherapy 1987, 31: 139–143.PubMedGoogle Scholar
  4. 4.
    Roosendaal R, Bakker-Woudenberg IA, van den Berghe-van Raffe M, Michel MF: Continuous versus intermittent administration of ceftazidime in experimentalKlebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrobial Agents and Chemotherapy 1986, 30: 403–408.PubMedGoogle Scholar
  5. 5.
    Barza M, Brusch J, Bergeron MG, Weinstein J: Penetration of antibiotics into fibrin loci in vivo. III. Intermittent vs continuous infusion and the effect of probenecid. Journal of Infectious Diseases 1974, 129: 73–78.PubMedGoogle Scholar
  6. 6.
    Craig WA, Ebert SC: Continuous infusion of β-lactam antibiotics. Antimicrobial Agents and Chemotherapy 1992, 36: 2577–2583.PubMedGoogle Scholar
  7. 7.
    Mc Donald PJ, Craig WA, Kunin CM: Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. Journal of Infectious Diseases 1977, 135: 217–223.Google Scholar
  8. 8.
    Craig WA, Ebert SC: Killing and regrowth of bacteria in vitro: a review. Scandinavian Journal of Infectious Diseases 1991, Supplement 74: 63–70.Google Scholar
  9. 9.
    Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA: Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. Journal of Infectious Diseases 1988, 158: 831–847.PubMedGoogle Scholar
  10. 10.
    Leggett JE, Ebert S, Fantin B, Craig WA: Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh infection and pneumonitis models. Scandinavian Journal of Infectious Diseases 1991, Supplement 74: 179–184.Google Scholar
  11. 11.
    Thijs JP, Vanderkelen B, Klastersky J: Pharmacological study of cefazolin during intermittent and continuous infusion: a cross-over investigation in humans. Antimicrobial Agents and Chemotherapy 1976, 10: 395–398.Google Scholar
  12. 12.
    Bodey GP, Ketchel SJ, Rodriguez V: A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine 1979, 67: 608–616.CrossRefPubMedGoogle Scholar
  13. 13.
    Daenen S, de Vries-Hospers H: Cure ofPseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet 1988, i: 937.Google Scholar
  14. 14.
    De Pauw BE, Kauw F, Muytjens H, Williams KJ, Bothof T: Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients. Journal of Antimicrobial Chemotherapy 1983, 12, Supplement A: 93–99.PubMedGoogle Scholar
  15. 15.
    Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. New England Journal of Medicine 1986, 315: 552–558.PubMedGoogle Scholar
  16. 16.
    Proost JH, Meijer DKF: MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Computers in Biology and Medicine 1992, 22: 155–163.CrossRefPubMedGoogle Scholar
  17. 17.
    Mouton JW, Horrevorts AM, Mulder PGH, Prens EP, Michel MF: Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusion in healthy volunteers. Antimicrobial Agents and Chemotherapy 1990, 34: 2307–2311.PubMedGoogle Scholar
  18. 18.
    Richards DM, Brogden RN: Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985, 29: 105–161.PubMedGoogle Scholar
  19. 19.
    Brodlie P, Henney C, Wood AJJ: Problems of administering drugs by continuous infusion. British Medical Journal 1974, 1: 383–385.PubMedGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1995

Authors and Affiliations

  • S. Daenen
    • 1
  • Z. Erjavec
    • 1
  • D. R. A. Uges
    • 2
  • H. G. De Vries-Hospers
    • 3
  • P. De Jonge
    • 4
  • M. R. Halie
    • 1
  1. 1.Department of HematologyAcademic HospitalGroningenThe Netherlands
  2. 2.Department of PharmacyAcademic HospitalGroningenThe Netherlands
  3. 3.Laboratory for Medical MicrobiologyAcademic HospitalGroningenThe Netherlands
  4. 4.Medical Department Glaxo B.V.ZeistThe Netherlands

Personalised recommendations